Priority 9 from the Multiple Sclerosis PSP
|UNCERTAINTY: Which treatments are effective for pain in people with multiple sclerosis? (JLA PSP Priority 9)|
|JLA question ID||0016/9|
|Explanatory note||Reliable up-to-date systematic reviews have revealed important continuing uncertainties about treatment effects|
McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD006146. DOI: 10.1002/14651858.CD006146.pub2.
|Systematic reviews that need extending or updating||
Straube S, Derry S, Moore RA, McQuay HJ. Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD007771. DOI: 10.1002/14651858.CD007771.pub2.
O'Connell NE, Wand BM, Marston L, Spencer S, DeSouza LH. Non-invasive brain stimulation techniques for chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD008208. DOI: 10.1002/14651858.CD008208.pub2.
|Systematic reviews in preparation||
Cui Y, Zhishun L, Marchese M, Lee MS, Wang J, Niu J. Acupuncture for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008210. DOI: 10.1002/14651858.CD008210. Accardi MC, Hallquist MN, Jensen MP, Patterson DR, Lynn SJ, Montgomery GH. Clinical hypnosis for chronic pain in adults (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 8. Art. No.: CD010691. DOI: 10.1002/14651858.CD010691.
|Ongoing controlled trials||
|Health Research Classification System category||Neurological|
|Extra information provided by this PSP|
|Original uncertainty examples||No examples provided. This is an indicative uncertainty and several submissions were merged to form this one.|
|Submitted by||4 patients ~ 1 carer|
|Outcomes to be measured||Management and or change of multiple sclerosis symptoms; adverse effects or complications; acceptability to patients or carers; time to return to work or normal activity; time in hospital and or needing health or social care services; health related quality of life; and costs.|
|PSP unique ID||0016|
|PSP name||Multiple Sclerosis|
|Total number of uncertainties identified by this PSP.||82 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)|
|Date of priority setting workshop||July 2013|